Evidence map›Paper›PMID 28631758›Full record

ArticleNature communications2017

Bioengineered constructs combined with exercise enhance stem cell-mediated treatment of volumetric muscle loss.

Marco Quarta, Melinda Cromie, Robert Chacon, Justin Blonigan, Victor Garcia, Igor Akimenko, Mark Hamer, Patrick Paine, Merel Stok, Joseph B Shrager and 1 more

Abstract read
In one paragraph

Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers.

0numbers the graph read from it
0cells of the map it votes in
176citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

176 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. 3D Printing Strategies for Bioengineering Human Cornea.Advanced healthcare materials · 2026
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Targeting C1q signaling in fibro-adipogenic progenitors prevents regenerative fibrosis of aged muscle.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  19. Article
  20. Review

116 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marco QuartaDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA.
Melinda CromieDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA.
Robert ChaconDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA.
Justin BloniganDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA.
Victor GarciaDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA.
Igor AkimenkoDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA.
Mark HamerDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA.
Patrick PaineDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA.
Merel StokErasmus Medical Center, Department of Hematology and Department of Pediatrics, Rotterdam 3000, The Netherlands.
Joseph B ShragerDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University School of Medicine and VA Palo Alto Health Care System, Stanford, California 94305, USA.
Thomas A RandoDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA.

Funding

Wnt signaling in muscle stem cell agingP01AG036695 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI THOMAS A. RANDO · 2011 to 2026
$29.3M
Technology Development P2CHD086843 · NICHD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI AMBROSIO, FABRISIA · 2015 to 2024
$10.5M
A New Muscle-Brain Axis Underlying the Cognitive Benefits of Physical ActivityR01AG047820 · NIA · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI RANDO, THOMAS A., WYSS-CORAY, TONY · 2013 to 2017
$3.5M
The Function and Regulation of Pax3 in Muscle Stem CellsR01AR062185 · NIAMS · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI RANDO, THOMAS A. · 2011 to 2015
$1.5M
Notch Signaling and Satellite Cell ActivationR01AG023806 · NIA · STANFORD UNIVERSITY · PI RANDO, THOMAS A. · 2005 to 2009
$1.2M
Muscle Stem Cell Therapy for Volumetric Muscle LossI01RX001222 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI HUANG, NGAN F. · 2014 to 2023
–
Regulation of Muscle Fibrosis in Response to Injury and AgingI01BX002324 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI RANDO, THOMAS A. · 2014 to 2021
–
BLRD VA I01 BX002324NIAMS NIH HHS R01 AR062185NIA NIH HHS P01 AG036695NIA NIH HHS R01 AG023806NIA NIH HHS R01 AG047820NICHD NIH HHS P2C HD086843
6 · The paper itself

Abstract

Volumetric muscle loss (VML) is associated with loss of skeletal muscle function, and current treatments show limited efficacy. Here we show that bioconstructs suffused with genetically-labelled muscle stem cells (MuSCs) and other muscle resident cells (MRCs) are effective to treat VML injuries in mice. Imaging of bioconstructs implanted in damaged muscles indicates MuSCs survival and growth, and ex vivo analyses show force restoration of treated muscles. Histological analysis highlights myofibre formation, neovascularisation, but insufficient innervation. Both innervation and in vivo force production are enhanced when implantation of bioconstructs is followed by an exercise regimen. Significant improvements are also observed when bioconstructs are used to treat chronic VML injury models. Finally, we demonstrate that bioconstructs made with human MuSCs and MRCs can generate functional muscle tissue in our VML model. These data suggest that stem cell-based therapies aimed to engineer tissue in vivo may be effective to treat acute and chronic VML.

Indexed as

AgedAnimalsBioreactorsCell- and Tissue-Based TherapyExerciseFemaleHumansMaleMiceMice, Inbred C57BLMice, Inbred NODMiddle AgedMuscle, SkeletalRegenerationStem Cell TransplantationTissue Engineering

Identifiers

PMID28631758
PMCPMC5481841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.